ClinicalRoche Stops Lung Cancer Immunotherapy Trial in Newest Disappointment

Roche Stops Lung Cancer Immunotherapy Trial in Newest Disappointment

-

The management of Roche has decided to stop the immunotherapy treatment trial for lung cancer, which is a further blow to making a breakthrough in cancer treatment. They stated that this decision was reached after realizing that the trial did not produce the expected results in their plan for developing viable strategies for new lung cancer treatments.

The phase 3 trial, dubbed SKYSCRAPER-06, was cut short due to the tepid performance of tiragolumab, Roche’s experimental cancer therapy. Tiragolumab, when combined with another medication, was shown to be inferior in slowing disease progression or extending survival compared to the combination of tiragolumab with Keytruda, an already established drug in Merck & Co’s portfolio. These findings raise significant questions about tiragolumab’s prospects and its ability to be a competitive contender in the lung cancer indication.
Roche’s stock also dipped by 2.3% to a three-week low after the news, signaling investors’ concern over the future prospects of the drug. JP Morgan’s analysts were also pessimistic about tiragolumab, claiming that the market may ignore all remaining possibilities for the drug in light of these results.
Tiragolumab is classified within the firm of anti-TIGIT, a new class of drugs that has garnered interest from many competitors in the market. Despite earlier trials and initial optimism in 2022 for this type of therapy in different patients, which also did not yield positive results in terms of changing disease progression, the current failure of the SKYSCRAPER-06 phase has been a severe blow to Roche in this therapeutic area.

Roche’s chief medical officer, Levi Garraway, conveyed disappointment over the trial’s conclusion in lung cancer treatment. Roche has suggested that it will take time to undertake a complete analysis of the results and look at the changes that might be required in the ongoing tiragolumab program, stating the necessity of rebalancing their strategy given the present difficulties.

Life Sciences Voice Logo mobile
+ posts

Latest news

Quantum Computing and Drug Discovery

Executive Summary Pharmaceutical drug discovery is fundamentally a problem of understanding molecules. Researchers need to determine how compounds interact with biological...

After a GLP-1 inhibitor lowers blood sugar crashes in a Ph. 3 victory, Amylyx prepares to push for approval

A $35 Million GLP-1 Bet Pays Off It looks like Amylyx Pharmaceuticals' $35 million gamble on the GLP-1 receptor agonist...

Biokin’s Iza-Bren Meets Primary Endpoint in Phase 3 Panku-Lung01 Lung Cancer Trial

Biokin Pharma reported positive results from the phase 3 Panku-Lung01 study of iza-bren, its EGFRxHER3 bispecific antibody-drug conjugate (ADC)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you